PGNY Progyny Forward Price-to-Revenue Multiple

Progyny Corp (PGNY) - corporate logo

Progyny, Inc. (PGNY) demonstrates a superior level of management and transparency in its dealings with Fortune 500 clients. The expected P/S valuation confirms market dynamics, with the metric holding around 1.60. Social responsibility and the digitalization of processes support the company's ESG status, while strict adherence to environmental standards minimizes its operational footprint within the reproductive health sector.

PGNY Progyny Inc: Market Cap to Projected Revenue in the range 07/04/2022 - 11/17/2026

Comprehensive metric breakdowns and analytics for Progyny, Inc. (PGNY)

- current price and projected stock value:
Comprehensive company analysis:PGNY (Progyny, Inc.)
Manufactured products of Progyny Corp

The margin of safety for Progyny, Inc. (PGNY) is determined by the ratio of market capitalization to projected sales. Operating exclusively in the US minimizes geopolitical risks, tying the business value to US corporate budgets. According to this forward price-to-sales chart, the current value of 1.60 reflects the cost per unit of future revenue. This indicator allows for the classification of the asset based on its degree of overbought status relative to the expected revenue growth rate.

Competitor analysis for Progyny, Inc.

Forward P/S Multiple HCA (HCA Healthcare, Inc.)|Price to Expected Revenue Ratio THC (Tenet Healthcare)|FMS - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio solventum.com|EHC: Forward P/S Multiple|UHS - Market Cap to Expected Sales Ratio|DVA (DaVita Corp) - Forward P/S Multiple|RDNT: Forward Price to Sales|Forward P/S Multiple OPCH|SGRY (surgerypartners.com) - Forward Price to Sales|Forward P/S Multiple PINC (Premier Inc)|National Vision - Price-to-Projected Revenue Ratio|Ardent Health - Forward P/S Multiple|Market Cap to Expected Sales Ratio Select Medical Corp SEM|ASTH: Forward P/S Multiple|Market Cap to Projected Revenue MD|USPH (US Physical Therapy Inc) - Forward P/S Multiple|PNTG: Forward Price to Sales|Price-to-Projected Revenue Ratio Organogenesis Corp (ORGO)|NUTX (Nutex Health Corp) - Forward Price to Sales|Forward P/S Multiple AUNA (Auna S.A.)|SBC Medical Group Holdings Inc (SBC) - Market Cap to Future Revenue Ratio|EOLS - Price-to-Projected Revenue Ratio|Forward Price to Sales CYH (Community Health Systems Inc)|SKIN (beautyhealth.com) - Forward Price-to-Revenue Multiple|Market Cap to Projected Revenue MDWD|Price-to-Projected Revenue Ratio biote Corp.|Market Cap to Future Revenue Ratio thejoint.com JYNT|Forward P/S Multiple DCGO|Forward Price-to-Revenue Multiple P3 Health PIII|Forward P/S Multiple GANX (Gain Therapeutics Inc.)|Forward P/S Multiple EUDA Health Holdings Limited EUDA|baselmedical.com - Forward P/S Multiple|CLGN: Price-to-Projected Revenue Ratio|Cuprina Holdings (Cayman) Ltd. (CUPR) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple Concord Medical|AMS (American Shared Hospital Services Inc) - Forward P/S Multiple|MEDIROM Corp (MRM) - Market Cap to Expected Sales Ratio|Forward P/S Multiple ALBT|Market Cap to Expected Sales Ratio DIH Holding|Forward P/S Multiple XAGE (carmellcosmetics.com)|NIVF: Market Cap to Projected Revenue|ATIP: Forward Price-to-Revenue Multiple|CareMax Medical Group - Price to Expected Revenue Ratio|Kindly MD (KDLY) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue MODV|Price-to-Projected Revenue Ratio Novo Integrated Sciences Corp|Market Cap to Future Revenue Ratio SunLink Health Systems SSY|Price-to-Projected Revenue Ratio IMAC Corp (BACK)